Report for Fujita KI

General

Full name :

First name :

Mail :

Zip Code :

City :

Country :

Email :

Phone :

Fax :

Website :

Directory :

References (2)

Title : Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients - Matsumoto_2020_Cancer.Chemother.Pharmacol__
Author(s) : Matsumoto N , Kubota Y , Ishida H , Sekido M , Ohkuma R , Ishiguro T , Hirasawa Y , Ariizumi H , Tsunoda T , Ikusue T , Kobayashi K , Hisamatsu A , Toshima H , Shimada K , Fujita KI
Ref : Cancer Chemother Pharmacol , : , 2020
Abstract : Matsumoto_2020_Cancer.Chemother.Pharmacol__
ESTHER : Matsumoto_2020_Cancer.Chemother.Pharmacol__
PubMedSearch : Matsumoto_2020_Cancer.Chemother.Pharmacol__
PubMedID: 32458030

Title : 123I-iomazenil whole-body imaging to detect hepatic carboxylesterase drug-metabolizing enzyme activity - Mizutani_2018_Nucl.Med.Commun_39_825
Author(s) : Mizutani A , Kobayashi M , Fujita KI , Takahashi K , Hokama T , Takasu H , Nishi K , Nishii R , Shikano N , Fukuchi K , Kawai K
Ref : Nucl Med Commun , 39 :825 , 2018
Abstract : Mizutani_2018_Nucl.Med.Commun_39_825
ESTHER : Mizutani_2018_Nucl.Med.Commun_39_825
PubMedSearch : Mizutani_2018_Nucl.Med.Commun_39_825
PubMedID: 29877992